Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;12(1):12-27.
doi: 10.1080/21541264.2021.1922071. Epub 2021 May 26.

Long noncoding RNAs: role and contribution in pancreatic cancer

K T Ramya Devi  1 , Dharshene Karthik  1   2 , TharunSelvam Mahendran  3 , M K Jaganathan  1 , Sanjana Prakash Hemdev  4
Affiliations
Review

Long noncoding RNAs: role and contribution in pancreatic cancer

K T Ramya Devi et al. Transcription. 2021 Feb.

Abstract

Noncoding RNAs are proclaimed to be expressed in various cancer types and one such type is found to be pancreatic ductal adenocarcinoma (PDAC). The long noncoding RNAs (LncRNAs) affect the migration, invasion, and growth of tumor cells by playing important roles in the process of epigenesis, post-transcription, and transcriptional regulation along with the maintenance of apoptosis and cell cycle. It is quite subtle whether the alterations in lncRNAs would impact PDAC progression and development. This review throws a spotlight on the lncRNAs associated with tumor functions: MALAT-1, HOTAIR, HOXA13, H19, LINC01559, LINC00460, SNHG14, SNHG16, DLX6-AS1, MSC-AS1, ABHD11-AS1, DUXAP8, DANCR, XIST, DLEU2, etc. are upregulated lncRNAs whereas GAS5, HMlincRNA717, MIAT, LINC01111, lncRNA KCNK15-AS1, etc. are downregulated lncRNAs inhibiting the invasion and progression of PDAC. These data provided helps in the assessment of lncRNAs in the development, metastasis, and occurrence of PDAC and also play a vital role in the evolution of biomarkers and therapeutic agents for the treatment of PDAC.

Keywords: Pancreatic ductal adenocarcinoma; biomarker; lncRNA; ncRNAs.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

References

    1. Halbrook CJ, Lyssiotis CA.. Employing metabolism to improve the diagnosis and treatment of Pancreatic cancer. Cancer Cell. 2017;31(1):5–19. - PubMed
    1. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694–9705. - PMC - PubMed
    1. Chu LC, Goggins MG, Fishman EK. Diagnosis and detection of pancreatic cancer. Cancer J. (United States). 2017;23:333–342. - PubMed
    1. Saluja A, Maitra A. Pancreatitis and pancreatic cancer. Gastroenterology. 2019;156(7):1937–1940. - PubMed
    1. Bhosale P, Cox V, Faria S, et al. Genetics of pancreatic cancer and implications for therapy. Abdom Radiol. 2018;43(2):404–414. - PubMed

MeSH terms

Substances

LinkOut - more resources